$CDNA
CareDx, Inc.

2016 Q4 Form 10-K Financial Statement

#000156459017006883 Filed on April 21, 2017

View on sec.gov

Income Statement

Concept 2016 Q4 2016 2015 Q4
Revenue $10.86M $40.63M $6.648M
YoY Change 63.34% 44.37% -16.4%
Cost Of Revenue $6.480M $10.88M $2.490M
YoY Change 160.24% 5.93% 13.18%
Gross Profit $4.380M $29.75M $4.160M
YoY Change 5.29% 66.47% -27.65%
Gross Profit Margin 40.34% 73.22% 62.58%
Selling, General & Admin $7.100M $31.89M $5.590M
YoY Change 27.01% 54.84% 40.45%
% of Gross Profit 162.1% 107.2% 134.38%
Research & Development $3.150M $12.39M $2.700M
YoY Change 16.67% 32.7% 107.69%
% of Gross Profit 71.92% 41.63% 64.9%
Depreciation & Amortization $720.0K $2.920M $220.0K
YoY Change 227.27% 266.83% 37.5%
% of Gross Profit 16.44% 9.82% 5.29%
Operating Expenses $10.22M $77.96M $8.620M
YoY Change 18.56% 94.54% 62.03%
Operating Profit -$5.840M -$37.33M -$4.460M
YoY Change 30.94% 212.87% -1137.21%
Interest Expense $1.020M -$1.860M -$250.0K
YoY Change -508.0% 17.2% -35.9%
% of Operating Profit
Other Income/Expense, Net $1.410M -$1.920M -$50.00K
YoY Change -2920.0% 921.28% 0.0%
Pretax Income -$16.43M -$41.36M -$4.760M
YoY Change 245.17% 201.76% 47500.0%
Income Tax -$720.0K -$1.606M $0.00
% Of Pretax Income
Net Earnings -$15.48M -$39.47M -$4.761M
YoY Change 225.2% 187.95% 95120.0%
Net Earnings / Revenue -142.58% -97.14% -71.62%
Basic Earnings Per Share -$0.73 -$2.39 -$0.40
Diluted Earnings Per Share -$0.73 -$2.39 -$0.40
COMMON SHARES
Basic Shares Outstanding 21.27M 16.50M 11.90M
Diluted Shares Outstanding 21.27M 16.50M 11.90M

Balance Sheet

Concept 2016 Q4 2016 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.30M $17.30M $29.90M
YoY Change -42.14% -42.14% -17.86%
Cash & Equivalents $17.26M $17.30M $29.89M
Short-Term Investments
Other Short-Term Assets $1.200M $1.200M $1.300M
YoY Change -7.69% -7.69% 160.0%
Inventory $5.500M $5.500M $766.0K
Prepaid Expenses
Receivables $2.768M $2.800M $2.400M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $26.70M $26.70M $34.36M
YoY Change -22.3% -22.38% -14.83%
LONG-TERM ASSETS
Property, Plant & Equipment $2.900M $2.900M $2.425M
YoY Change 19.59% 20.83% 23.22%
Goodwill $13.84M $12.01M
YoY Change 15.28% 0.0%
Intangibles $6.650M
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $49.00K
YoY Change 308.16% 0.0% 96.0%
Total Long-Term Assets $50.00M $50.00M $21.28M
YoY Change 135.01% 135.85% 2.31%
TOTAL ASSETS
Total Short-Term Assets $26.70M $26.70M $34.36M
Total Long-Term Assets $50.00M $50.00M $21.28M
Total Assets $76.70M $76.70M $55.64M
YoY Change 37.86% 37.95% -9.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.100M $3.100M $1.644M
YoY Change 88.56% 93.75% 45.74%
Accrued Expenses $9.400M $9.400M $5.500M
YoY Change 70.91% 70.91% 120.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $22.85M $22.80M $2.866M
YoY Change 697.14% 686.21% -51.92%
Total Short-Term Liabilities $40.83M $40.80M $10.15M
YoY Change 302.21% 300.0% -8.83%
LONG-TERM LIABILITIES
Long-Term Debt $1.098M $1.100M $12.89M
YoY Change -91.48% -91.47% 136.42%
Other Long-Term Liabilities $1.222M $9.000M $28.00K
YoY Change 4264.29% 190.32% 0.0%
Total Long-Term Liabilities $2.320M $10.10M $12.92M
YoY Change -82.04% -36.88% 135.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $40.83M $40.80M $10.15M
Total Long-Term Liabilities $2.320M $10.10M $12.92M
Total Liabilities $56.97M $57.20M $26.14M
YoY Change 117.9% 119.16% 31.75%
SHAREHOLDERS EQUITY
Retained Earnings -$212.6M -$173.1M
YoY Change 22.8% 8.6%
Common Stock $235.7M $12.00K
YoY Change 1964016.67% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.48M $19.50M $29.49M
YoY Change
Total Liabilities & Shareholders Equity $76.73M $76.70M $55.64M
YoY Change 37.91% 37.95% -9.0%

Cashflow Statement

Concept 2016 Q4 2016 2015 Q4
OPERATING ACTIVITIES
Net Income -$15.48M -$39.47M -$4.761M
YoY Change 225.2% 187.95% 95120.0%
Depreciation, Depletion And Amortization $720.0K $2.920M $220.0K
YoY Change 227.27% 266.83% 37.5%
Cash From Operating Activities -$3.060M -$16.52M -$3.970M
YoY Change -22.92% 69.47% 451.39%
INVESTING ACTIVITIES
Capital Expenditures $80.00K $549.0K -$80.00K
YoY Change -200.0% -54.21% -80.0%
Acquisitions $20.57M
YoY Change
Other Investing Activities $0.00 -$20.57M $0.00
YoY Change -100.0%
Cash From Investing Activities $70.00K -$21.12M -$80.00K
YoY Change -187.5% 1660.08% -86.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.130M 24.93M -10.00K
YoY Change 21200.0% 465.24% -99.23%
NET CHANGE
Cash From Operating Activities -3.060M -16.52M -3.970M
Cash From Investing Activities 70.00K -21.12M -80.00K
Cash From Financing Activities -2.130M 24.93M -10.00K
Net Change In Cash -5.120M -12.63M -4.060M
YoY Change 26.11% 93.18% 55.56%
FREE CASH FLOW
Cash From Operating Activities -$3.060M -$16.52M -$3.970M
Capital Expenditures $80.00K $549.0K -$80.00K
Free Cash Flow -$3.140M -$17.07M -$3.890M
YoY Change -19.28% 55.92% 1115.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21391266
CY2016Q2 dei Entity Public Float
EntityPublicFloat
49002299
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29888000
CY2015Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
2367000
CY2015Q4 us-gaap Inventory Net
InventoryNet
766000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1341000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
34362000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2425000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
147000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
49000
CY2015Q4 us-gaap Assets
Assets
55638000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1644000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2366000
CY2015Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
242000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
142000
CY2016Q4 cdna Business Acquisition Deferred Payment Consideration With Interest Accretion
BusinessAcquisitionDeferredPaymentConsiderationWithInterestAccretion
5445000
CY2015Q4 cdna Business Acquisition Deferred Payment Consideration With Interest Accretion
BusinessAcquisitionDeferredPaymentConsiderationWithInterestAccretion
0
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
22846000
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2866000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40832000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10152000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1301000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
759000
CY2016 us-gaap License And Services Revenue
LicenseAndServicesRevenue
236000
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6650000
CY2015Q4 us-gaap Goodwill
Goodwill
12005000
CY2016Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
5208000
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1098000
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
492000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1222000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20725000
CY2016 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-456000
CY2015 us-gaap Operating Expenses
OperatingExpenses
40076000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-37332000
CY2015 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
27881000
CY2014 us-gaap Revenues
Revenues
27306000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3659000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212553000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
19482000
CY2016Q4 us-gaap Minority Interest
MinorityInterest
279000
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19761000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76730000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21278373
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21278373
CY2016 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
29680000
CY2016 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
10715000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3846000
CY2016 us-gaap Revenues
Revenues
40631000
CY2014 us-gaap Cost Of Services
CostOfServices
8541000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
1250000
CY2016 us-gaap Cost Of Services
CostOfServices
10882000
CY2016 us-gaap Cost Of Goods Sold
CostOfGoodsSold
10240000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12385000
CY2015 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-126000
CY2016 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11166000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8436000
CY2014 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1239000
CY2015 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8349000
CY2014 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6472000
CY2015Q4 us-gaap Minority Interest
MinorityInterest
0
CY2015Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
28000
CY2015Q4 us-gaap Liabilities
Liabilities
26144000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
29494000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173084000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
29494000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55638000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1426000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
703000
CY2015Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
0
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12887000
CY2015Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
948000
CY2015Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2892000
CY2014 us-gaap Cost Of Goods Sold
CostOfGoodsSold
0
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11902363
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9333000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2015 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
15625000
CY2016 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
3944000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2014 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
25842000
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
0
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-11932000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-188000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11902363
CY2014 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
263000
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1464000
CY2015 us-gaap Revenues
Revenues
28144000
CY2015 us-gaap Cost Of Services
CostOfServices
10273000
CY2014 us-gaap Operating Expenses
OperatingExpenses
26056000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-78000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13707000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-719000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1500000
CY2015 us-gaap Profit Loss
ProfitLoss
-13707000
CY2014 us-gaap Profit Loss
ProfitLoss
781000
CY2015 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2014 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-13707000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
781000
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11860885
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5815928
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11860885
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9283001
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2015 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-13707000
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
6057000
CY2016Q4 us-gaap Liabilities
Liabilities
56969000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
21000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
235673000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
202566000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12247000
CY2016 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
13021000
CY2014 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2016 us-gaap Operating Expenses
OperatingExpenses
77963000
CY2016 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1860000
CY2015 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1587000
CY2014 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2116000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1920000
CY2016 us-gaap Unrealized Gain Loss On Derivatives And Commodity Contracts
UnrealizedGainLossOnDerivativesAndCommodityContracts
-250000
CY2015 us-gaap Unrealized Gain Loss On Derivatives And Commodity Contracts
UnrealizedGainLossOnDerivativesAndCommodityContracts
0
CY2014 us-gaap Unrealized Gain Loss On Derivatives And Commodity Contracts
UnrealizedGainLossOnDerivativesAndCommodityContracts
225000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41362000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1606000
CY2016 us-gaap Profit Loss
ProfitLoss
-39756000
CY2016 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-287000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-39469000
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.39
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.39
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16496911
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16496911
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3727000
CY2016 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-43483000
CY2014 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
781000
CY2016 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-355000
CY2015 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0
CY2014 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
0
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43128000
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-150675000
CY2014 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
0
CY2014 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
149444000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5108000
CY2014 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
-539000
CY2014 cdna Issuance Of Common Stock Initial Public Offering
IssuanceOfCommonStockInitialPublicOffering
35511000
CY2014 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
34000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
535000
CY2014Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
41296000
CY2015 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
223000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
46000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
203000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1343000
CY2015 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
90000
CY2016 cdna Stock Issued During Period Value Business Acquisitions
StockIssuedDuringPeriodValueBusinessAcquisitions
7205000
CY2016 cdna Stock Issued During Period Value Preferred Stock Issued Through Private Placement And Subsequent Financing
StockIssuedDuringPeriodValuePreferredStockIssuedThroughPrivatePlacementAndSubsequentFinancing
13064000
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5000
CY2016 cdna Stock Issued During Period Value Stock Issued Through Private Placement And Subsequent Financing
StockIssuedDuringPeriodValueStockIssuedThroughPrivatePlacementAndSubsequentFinancing
2596000
CY2016 cdna Issuance Of Common Stock Initial Public Offering
IssuanceOfCommonStockInitialPublicOffering
7925000
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
304000
CY2016 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
304000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13707000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
781000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-620000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
417000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-492000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
80000
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
168000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
535000
CY2016 cdna Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
45000
CY2016 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-999000
CY2015 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
823000
CY2014 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
310000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1694000
CY2016 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
634000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2920000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
796000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
512000
CY2016 us-gaap Cost Of Goods Sold Depreciation
CostOfGoodsSoldDepreciation
4175000
CY2015 us-gaap Cost Of Goods Sold Depreciation
CostOfGoodsSoldDepreciation
0
CY2014 us-gaap Cost Of Goods Sold Depreciation
CostOfGoodsSoldDepreciation
0
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
2000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
1998000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
1341000
CY2015 cdna Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
130000
CY2014 cdna Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
727000
CY2016 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
-101000
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
247000
CY2014 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
799000
CY2016 cdna Non Cash Income Tax Benefit In Connection With Business Acquisition
NonCashIncomeTaxBenefitInConnectionWithBusinessAcquisition
0
CY2015 cdna Non Cash Income Tax Benefit In Connection With Business Acquisition
NonCashIncomeTaxBenefitInConnectionWithBusinessAcquisition
0
CY2014 cdna Non Cash Income Tax Benefit In Connection With Business Acquisition
NonCashIncomeTaxBenefitInConnectionWithBusinessAcquisition
1500000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1047000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-320000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
489000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
510000
CY2016 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
977000
CY2015 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
682000
CY2014 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
298000
CY2016 us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
21000
CY2015 us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
1000
CY2014 us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
-2563000
CY2016 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-105000
CY2015 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1240000
CY2014 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
364000
CY2016 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1340000
CY2015 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0
CY2014 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16523000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9752000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3350000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
549000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1199000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
733000
CY2016 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
20568000
CY2015 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
CY2014 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
600000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-21117000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1199000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1333000
CY2016 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2015 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2014 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
39246000
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3733000
CY2016 us-gaap Proceeds From Issuance Of Subordinated Long Term Debt
ProceedsFromIssuanceOfSubordinatedLongTermDebt
0
CY2015 us-gaap Proceeds From Issuance Of Subordinated Long Term Debt
ProceedsFromIssuanceOfSubordinatedLongTermDebt
0
CY2014 us-gaap Proceeds From Issuance Of Subordinated Long Term Debt
ProceedsFromIssuanceOfSubordinatedLongTermDebt
4982000
CY2016 cdna Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
7926000
CY2015 cdna Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
0
CY2014 cdna Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
0
CY2016 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
CY2014 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
CY2016 cdna Proceeds From Private Placement And Subsequent Financing Net Of Issuance Costs
ProceedsFromPrivatePlacementAndSubsequentFinancingNetOfIssuanceCosts
20622000
CY2015 cdna Proceeds From Private Placement And Subsequent Financing Net Of Issuance Costs
ProceedsFromPrivatePlacementAndSubsequentFinancingNetOfIssuanceCosts
0
CY2014 cdna Proceeds From Private Placement And Subsequent Financing Net Of Issuance Costs
ProceedsFromPrivatePlacementAndSubsequentFinancingNetOfIssuanceCosts
0
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
46000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19000
CY2016 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
304000
CY2015 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
203000
CY2014 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0
CY2015 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
11466000
CY2014 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
4528000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
24927000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4408000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
35986000
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
83000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-12630000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6543000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
31303000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36431000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5128000
CY2016 us-gaap Interest Paid Net
InterestPaidNet
867000
CY2015 us-gaap Interest Paid Net
InterestPaidNet
1364000
CY2014 us-gaap Interest Paid Net
InterestPaidNet
1207000
CY2016 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0
CY2015 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
25000
CY2014 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
193000
CY2016 cdna Common Stock Issued For Acquisition
CommonStockIssuedForAcquisition
7205000
CY2015 cdna Common Stock Issued For Acquisition
CommonStockIssuedForAcquisition
0
CY2014 cdna Common Stock Issued For Acquisition
CommonStockIssuedForAcquisition
14242000
CY2016 cdna Debt Assumed As Part Of Acquisition
DebtAssumedAsPartOfAcquisition
13421000
CY2015 cdna Debt Assumed As Part Of Acquisition
DebtAssumedAsPartOfAcquisition
0
CY2014 cdna Debt Assumed As Part Of Acquisition
DebtAssumedAsPartOfAcquisition
0
CY2016Q4 cdna Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
5700000
CY2015Q4 cdna Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
0
CY2014Q4 cdna Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
0
CY2016 cdna Conversion Of Convertible Preferred Stock To Common Stock At Private Placement And Subsequent Financing
ConversionOfConvertiblePreferredStockToCommonStockAtPrivatePlacementAndSubsequentFinancing
13064000
CY2015 cdna Conversion Of Convertible Preferred Stock To Common Stock At Private Placement And Subsequent Financing
ConversionOfConvertiblePreferredStockToCommonStockAtPrivatePlacementAndSubsequentFinancing
0
CY2014 cdna Conversion Of Convertible Preferred Stock To Common Stock At Private Placement And Subsequent Financing
ConversionOfConvertiblePreferredStockToCommonStockAtPrivatePlacementAndSubsequentFinancing
0
CY2016 cdna Conversion Of Convertible Preferred Stock To Common Stock At Initial Public Offering
ConversionOfConvertiblePreferredStockToCommonStockAtInitialPublicOffering
0
CY2015 cdna Conversion Of Convertible Preferred Stock To Common Stock At Initial Public Offering
ConversionOfConvertiblePreferredStockToCommonStockAtInitialPublicOffering
0
CY2014 cdna Conversion Of Convertible Preferred Stock To Common Stock At Initial Public Offering
ConversionOfConvertiblePreferredStockToCommonStockAtInitialPublicOffering
149444000
CY2016 cdna Conversion Of Convertible Preferred Stock Warrants To Common Stock Warrants
ConversionOfConvertiblePreferredStockWarrantsToCommonStockWarrants
0
CY2015 cdna Conversion Of Convertible Preferred Stock Warrants To Common Stock Warrants
ConversionOfConvertiblePreferredStockWarrantsToCommonStockWarrants
0
CY2014 cdna Conversion Of Convertible Preferred Stock Warrants To Common Stock Warrants
ConversionOfConvertiblePreferredStockWarrantsToCommonStockWarrants
539000
CY2016 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2015 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2014 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
5108000
CY2016 us-gaap Stock Issued1
StockIssued1
304000
CY2015 us-gaap Stock Issued1
StockIssued1
223000
CY2014 us-gaap Stock Issued1
StockIssued1
34000
CY2016 cdna Debt Conversion Converted Instrument Common Stock Warrants Issued
DebtConversionConvertedInstrumentCommonStockWarrantsIssued
0
CY2015 cdna Debt Conversion Converted Instrument Common Stock Warrants Issued
DebtConversionConvertedInstrumentCommonStockWarrantsIssued
90000
CY2014 cdna Debt Conversion Converted Instrument Common Stock Warrants Issued
DebtConversionConvertedInstrumentCommonStockWarrantsIssued
0
CY2014 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2016 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i)&#160;revenue recognition, (ii)&#160;the differences between amounts billed and estimated receipts from payers, (iii)&#160;the determination of the accruals for clinical studies, (iv)&#160;the determination of refunds to be requested by third-party payers, (v)&#160;the fair value of assets and liabilities, including from acquisitions, (vi)&#160;inventory valuation, (vii) the valuation of warrants, Series A Preferred, and common stock issued in the Private Placement and Subsequent Financing, (viii)&#160;the fair value of contingent consideration in a business acquisition, (ix) the fair value of embedded derivatives, (x) measurement of stock-based compensation expense, (xi)&#160;the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xii)&#160;any impairment of long-lived assets, including in-process technology and goodwill, and (xiii)&#160;legal contingencies. Actual results could differ from those estimates. </p></div>
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company&#8217;s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper and various bank deposit accounts. These financial instruments were held in Company accounts at eight financial institutions. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its accounts receivable, which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers, and sales of Olerup SSP products to distributors, strategic partners and end customers in Europe, Middle East and Africa, the U.S., Latin America and other geographic regions. The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the years ended December&#160;31, 2016, 2015 and 2014, approximately 44%, 50% and 51%, respectively, of testing revenue was paid for by Medicare. No other payers represented more than 10% of testing revenue for these periods. Product revenue accounted for 26% of total revenue for the year ended December 31, 2016. No payer accounted for more than 10% of product revenue for this period. At December&#160;31, 2016 and 2015, approximately 27% and 35%, respectively, of accounts receivable was due from Medicare. At December 31, 2016 and 2015, approximately 6 % and 21% of accounts receivable was due from Aetna, respectively. No other payer represented more than 10% of accounts receivable at December&#160;31, 2016 or 2015. </p></div>
CY2016 us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product Revenue</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when persuasive evidence of an arrangement exists, the product is complete and tested and has been shipped or delivered, as required to transfer title and risk of loss, the sales price is fixed and determinable, collection of the resulting receivable is reasonably assured, there are no material contingencies and the Company does not have significant obligations for future performance. When collectability is not reasonably assured, the Company defers the revenue until the cash is received. Provisions for estimated future product returns and allowances are recorded in the period of the sale based on the historical and anticipated future rate of returns. Revenue is recorded net of any discounts given to the buyer. </p></div>
CY2016 us-gaap Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaboration and License Revenue </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company&#8217;s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes contingent consideration received from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved, which the Company believes is consistent with the substance of its performance under its various license and collaboration agreements. The Company did not recognize any revenue connected with milestones during the years ended December&#160;31, 2016, 2015 or 2014. </p></div>
CY2016 us-gaap Advertising Cost Policy Expensed Advertising Cost
AdvertisingCostPolicyExpensedAdvertisingCost
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advertising Expenses</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All advertising costs are expensed as incurred. Advertising expenses were insignificant during all of the periods presented.</p></div>
CY2016 cdna Fair Value Of Derivative Gain Loss On Derivative Net
FairValueOfDerivativeGainLossOnDerivativeNet
0
CY2015 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0
CY2014 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
364000
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016 us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.
CY2016 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2015 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2016 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2016Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
24000000
CY2016 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 6.85
CY2016 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.145985401
CY2016 cdna Stockholders Equity Reverse Stock Split Effective Date
StockholdersEquityReverseStockSplitEffectiveDate
2014-07-14
CY2015 cdna Fair Value Of Derivative Gain Loss On Derivative Net
FairValueOfDerivativeGainLossOnDerivativeNet
0
CY2014 cdna Fair Value Of Derivative Gain Loss On Derivative Net
FairValueOfDerivativeGainLossOnDerivativeNet
118000
CY2016 cdna Derivative Gain Loss On Extinguishment Of Debt
DerivativeGainLossOnExtinguishmentOfDebt
0
CY2015 cdna Derivative Gain Loss On Extinguishment Of Debt
DerivativeGainLossOnExtinguishmentOfDebt
0
CY2014 cdna Derivative Gain Loss On Extinguishment Of Debt
DerivativeGainLossOnExtinguishmentOfDebt
120000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-39469000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-13707000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
907000
CY2016 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2015 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2014 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
2972051
CY2016 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
CY2015 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
CY2014 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
134341
CY2016 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
360681
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5323480
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1984586
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
753322
CY2016Q2 cdna Preferred Stock Issued Shares Private Placement
PreferredStockIssuedSharesPrivatePlacement
4630145
CY2016Q2 cdna Preferred Stock Issued Shares Subsequent Financing
PreferredStockIssuedSharesSubsequentFinancing
4630145
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1074000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
126000
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
948000
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
4958000
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
206000
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
5700000
CY2016 cdna Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2015 cdna Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2016Q2 cdna Minimum Lender Required Proceeds From Issuance Of Private Placement Offer
MinimumLenderRequiredProceedsFromIssuanceOfPrivatePlacementOffer
12000000
CY2016Q4 cdna Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
50620000
CY2016 cdna Foreign Currency Effect
ForeignCurrencyEffect
68000
CY2016 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
16922000
CY2016 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-2067000
CY2016 us-gaap Number Of Reporting Units
NumberOfReportingUnits
2
CY2016 us-gaap New Date Of Annual Goodwill Impairment Test
NewDateOfAnnualGoodwillImpairmentTest
The Company tested its goodwill for impairments as of December 1, 2016. The Company performed step one of its annual Goodwill impairment test
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
31560000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1721000
CY2016 us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
-3365000
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
26474000
CY2016Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
38210000
CY2016Q4 cdna Intangible Assets Excluding Goodwill Accumulated Amortization
IntangibleAssetsExcludingGoodwillAccumulatedAmortization
1721000
CY2016 cdna Intangible Assets Excluding Goodwill Foreign Currency Translation Gain Loss
IntangibleAssetsExcludingGoodwillForeignCurrencyTranslationGainLoss
-3365000
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1700000
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2016Q4 cdna Indefinite Lived Intangible Assets Excluding Goodwill Gross
IndefiniteLivedIntangibleAssetsExcludingGoodwillGross
6700000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2470000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2315000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2252000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2252000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
2252000
CY2016Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
14933000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4199000
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
237000
CY2013Q2 cdna Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
263000
CY2013Q2 cdna Upfront Payment In Cash
UpfrontPaymentInCash
387500
CY2013Q2 cdna Upfront Payment In Cash
UpfrontPaymentInCash
408000
CY2016 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
2000
CY2015 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
46000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
440000
CY2014 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
36000
CY2016 us-gaap Royalty Revenue
RoyaltyRevenue
194000
CY2015 us-gaap Royalty Revenue
RoyaltyRevenue
179000
CY2014 us-gaap Royalty Revenue
RoyaltyRevenue
221000
CY2016Q4 cdna Royalty Revenue Receivable
RoyaltyRevenueReceivable
0
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
338000
CY2013Q2 cdna Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
250000
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
159000
CY2015Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1103000
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
529000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17086000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14298000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14155000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11873000
CY2016 us-gaap Adjustment For Amortization
AdjustmentForAmortization
204000
CY2015 us-gaap Adjustment For Amortization
AdjustmentForAmortization
79000
CY2014 us-gaap Adjustment For Amortization
AdjustmentForAmortization
59000
CY2016Q4 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
1375000
CY2015Q4 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
756000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
862000
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
620000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
880000
CY2016Q4 cdna Accrued Debt Financing Fees Current
AccruedDebtFinancingFeesCurrent
600000
CY2015Q4 cdna Accrued Debt Financing Fees Current
AccruedDebtFinancingFeesCurrent
0
CY2016Q4 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
524000
CY2015Q4 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
426000
CY2016Q4 cdna Accrued Over Payments And Refunds
AccruedOverPaymentsAndRefunds
281000
CY2015Q4 cdna Accrued Over Payments And Refunds
AccruedOverPaymentsAndRefunds
163000
CY2016Q4 cdna Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
176000
CY2015Q4 cdna Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
0
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
374000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
258000
CY2016Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
68000
CY2015Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
71000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1500000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
74000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
24000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
5000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
0
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
0
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
103000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
9000
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
94000
CY2016Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
26000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2133000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2092000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2082000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2041000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
8349000
CY2016Q3 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
1300000
CY2016Q4 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
1000000
CY2016Q4 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
100000
CY2016 cdna Description Of Agreement Expected Expiration Year
DescriptionOfAgreementExpectedExpirationYear
The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.
CY2015Q4 cdna Royalty Revenue Receivable
RoyaltyRevenueReceivable
0
CY2015Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
20000000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
332995
CY2016 us-gaap Debt Instrument Description Of Variable Rate Basis
DebtInstrumentDescriptionOfVariableRateBasis
Draw A bore interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the Lender.
CY2015Q1 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0200
CY2016 us-gaap Line Of Credit Facility Initiation Date1
LineOfCreditFacilityInitiationDate1
2015-01-30
CY2016 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2018-12-01
CY2016Q4 cdna Debt Issuance And Discount Component Of Recognized Debt Liability Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent
200000
CY2015Q4 cdna Debt Issuance And Discount Component Of Recognized Debt Liability Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent
200000
CY2016Q4 cdna Debt Issuance And Discount Component Of Recognized Debt Liability Non Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent
0
CY2015Q4 cdna Debt Issuance And Discount Component Of Recognized Debt Liability Non Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent
100000
CY2016 cdna Prepayment Penalty
PrepaymentPenalty
0.00
CY2016 us-gaap Debt Instrument Description
DebtInstrumentDescription
The Company agreed to issue to the Lender warrants to purchase shares of the Company’s common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche.
CY2015Q1 cdna Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
90000
CY2016 us-gaap Default Longterm Debt Description Of Violation Or Event Of Default
DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault
Upon the occurrence of an event of default, a default interest rate of an additional 5.00% may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.
CY2016 cdna Percentage Of Default Interest Payment
PercentageOfDefaultInterestPayment
0.0500
CY2016Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
800000
CY2016Q4 cdna Long Term Debt Maturities Repayments In Next Twelve Months
LongTermDebtMaturitiesRepaymentsInNextTwelveMonths
23032000
CY2016Q4 cdna Long Term Debt Maturities Repayments In Year Two
LongTermDebtMaturitiesRepaymentsInYearTwo
1098000
CY2016Q4 cdna Long Term Debt Maturities Repayments
LongTermDebtMaturitiesRepayments
24130000
CY2016Q4 cdna Debt Discount And Issuance Costs
DebtDiscountAndIssuanceCosts
-186000
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
23944000
CY2016Q2 cdna Common Stock Purchase Price
CommonStockPurchasePrice
3.99
CY2016Q2 us-gaap Fees And Commissions Transfer Agent
FeesAndCommissionsTransferAgent
1800000
cdna Additional Issued Units
AdditionalIssuedUnits
334169
CY2016Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
1700000
CY2016Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1002507
CY2016 cdna Estimated Fair Value Of Warrant Liability Remeasurement Charge
EstimatedFairValueOfWarrantLiabilityRemeasurementCharge
300000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
940884
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
585345
CY2014 cdna Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Assumed In Acquisition
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAssumedInAcquisition
0
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
20591
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
13781
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
718007
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
357075
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
652078
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
8200
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
77660
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
5329
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
361672
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
512575
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
597470
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
61305
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
269212
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
107601
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
365074
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
466965
CY2014 cdna Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Reserved For Available For Issuance
ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedForAvailableForIssuance
0
CY2014 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Assumed From Acquisitions In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedFromAcquisitionsInPeriod
23229
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
9363
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1031804
CY2015 cdna Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Reserved For Available For Issuance
ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedForAvailableForIssuance
0
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
23576
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1577317
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5688
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1792286
CY2016Q4 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
990371
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1757309
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.99
CY2014 cdna Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved
0
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.76
CY2014 cdna Share Based Compensation Arrangements By Share Based Payment Award Options Shares Assumed From Acquisition Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsSharesAssumedFromAcquisitionWeightedAverageExercisePrice
2.06
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.14
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.36
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.74
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.36
CY2015 cdna Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved
0
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.09
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.94
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.13
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
10.36
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.87
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.91
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.29
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.64
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
8.88
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.15
CY2016 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
6.05
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.15
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7100
CY2016Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1792286
CY2016 cdna Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options Weighted Average Remaining Contractual Term
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptionsWeightedAverageRemainingContractualTerm
P7Y6M4D
CY2016Q4 cdna Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options Weighted Average Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptionsWeightedAverageExercisePrice
6.14
CY2016Q4 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
766938
CY2016Q4 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
6.28
CY2016 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
P6Y6M18D
CY2016 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P8Y8M12D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y5M27D
CY2016Q4 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
427000
CY2016Q4 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
427000
CY2016Q4 us-gaap Share Price
SharePrice
2.70
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.05
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.53
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.81
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1100000
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1600000
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1998000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1341000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
535000
CY2016 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2016 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21753000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-13707000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-719000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-19609000
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
2.088
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
71925000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4947000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
49000
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
11000
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
32000
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2014 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
92000
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-251000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1500000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-49000
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-1398000
CY2015 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2014 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1698000
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1500000
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.005
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.019
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.095
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.168
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.311
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1.906
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.013
CY2015 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.000
CY2014 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.000
CY2016 cdna Effective Income Tax Rate Reconciliation Preferred Stock Warrant Revaluation
EffectiveIncomeTaxRateReconciliationPreferredStockWarrantRevaluation
-0.002
CY2015 cdna Effective Income Tax Rate Reconciliation Preferred Stock Warrant Revaluation
EffectiveIncomeTaxRateReconciliationPreferredStockWarrantRevaluation
0.000
CY2014 cdna Effective Income Tax Rate Reconciliation Preferred Stock Warrant Revaluation
EffectiveIncomeTaxRateReconciliationPreferredStockWarrantRevaluation
-0.007
CY2016 cdna Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
0.000
CY2015 cdna Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
0.000
CY2014 cdna Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
-0.058
CY2016 cdna Effective Income Tax Rate Reconciliation Liability Contingent For Unconsolidated Subsidiary Percent
EffectiveIncomeTaxRateReconciliationLiabilityContingentForUnconsolidatedSubsidiaryPercent
-0.004
CY2015 cdna Effective Income Tax Rate Reconciliation Liability Contingent For Unconsolidated Subsidiary Percent
EffectiveIncomeTaxRateReconciliationLiabilityContingentForUnconsolidatedSubsidiaryPercent
0.000
CY2014 cdna Effective Income Tax Rate Reconciliation Liability Contingent For Unconsolidated Subsidiary Percent
EffectiveIncomeTaxRateReconciliationLiabilityContingentForUnconsolidatedSubsidiaryPercent
-0.382
CY2016 cdna Effective Income Tax Rate Reconciliation Acquisition Costs
EffectiveIncomeTaxRateReconciliationAcquisitionCosts
-0.012
CY2015 cdna Effective Income Tax Rate Reconciliation Acquisition Costs
EffectiveIncomeTaxRateReconciliationAcquisitionCosts
-0.032
CY2014 cdna Effective Income Tax Rate Reconciliation Acquisition Costs
EffectiveIncomeTaxRateReconciliationAcquisitionCosts
-0.367
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
-0.108
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
0.000
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
0.000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.003
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.022
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.013
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.039
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
1274000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1088000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
79234000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
76295000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2939000
CY2016Q4 cdna Deferred Tax Liabilities Assets Net Property Plant And Equipment
DeferredTaxLiabilitiesAssetsNetPropertyPlantAndEquipment
-195000
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
8979000
CY2016Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
212000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8996000
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
6057000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
65957000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4533000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
1125000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
698000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
72313000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
70053000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2260000
CY2015Q4 cdna Deferred Tax Liabilities Assets Net Property Plant And Equipment
DeferredTaxLiabilitiesAssetsNetPropertyPlantAndEquipment
-95000
CY2015Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2355000
CY2015Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
0
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2260000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6200000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3700000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2431000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2054000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2196000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2489000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
372000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
83000
CY2016 cdna Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
332000
CY2015 cdna Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
5000
CY2014 cdna Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
-225000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5252000
CY2016Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
2600000
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
300000
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2014Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2016 cdna Intersegment Sales
IntersegmentSales
0
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2920000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
796000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
512000
CY2016Q1 us-gaap Revenues
Revenues
6562000
CY2016Q2 us-gaap Revenues
Revenues
10735000
CY2016Q3 us-gaap Revenues
Revenues
12475000
CY2016Q4 us-gaap Revenues
Revenues
10859000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-9752000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-10470000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-3764000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-15483000
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19098626
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11814467
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11835405
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11890057
CY2015Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11902325
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2016Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11969714
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13568120
CY2016Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21270151
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11969714
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13568120
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19481424
CY2016Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21270151
CY2016Q1 us-gaap Assets
Assets
48834000
CY2016Q2 us-gaap Assets
Assets
100453000
CY2016Q3 us-gaap Assets
Assets
102092000
CY2016Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11368000
CY2016Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10072000
CY2016Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8496000
CY2015Q1 us-gaap Revenues
Revenues
7216000
CY2015Q2 us-gaap Revenues
Revenues
7129000
CY2015Q3 us-gaap Revenues
Revenues
7151000
CY2015Q4 us-gaap Revenues
Revenues
6648000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-2272000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-3185000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-3489000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-4761000
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11814467
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11835405
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11890057
CY2015Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11902325
CY2015Q1 us-gaap Assets
Assets
63277000
CY2015Q2 us-gaap Assets
Assets
61366000
CY2015Q3 us-gaap Assets
Assets
59342000
CY2015Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14609000
CY2015Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
13389000
CY2015Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12125000

Files In Submission

Name View Source Status
0001564590-17-006883-index-headers.html Edgar Link pending
0001564590-17-006883-index.html Edgar Link pending
0001564590-17-006883.txt Edgar Link pending
0001564590-17-006883-xbrl.zip Edgar Link pending
cdna-10k_20161231.htm Edgar Link pending
cdna-20161231.xml Edgar Link completed
cdna-20161231.xsd Edgar Link pending
cdna-20161231_cal.xml Edgar Link unprocessable
cdna-20161231_def.xml Edgar Link unprocessable
cdna-20161231_lab.xml Edgar Link unprocessable
cdna-20161231_pre.xml Edgar Link unprocessable
cdna-ex1043_1919.htm Edgar Link pending
cdna-ex211_641.htm Edgar Link pending
cdna-ex231_6.htm Edgar Link pending
cdna-ex311_1019.htm Edgar Link pending
cdna-ex312_1018.htm Edgar Link pending
cdna-ex321_1017.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201704211913177038035.jpg Edgar Link pending
g201704211913530188035.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending